Editorial Policy

Every article goes through four steps before publication, with the source file, publication date, and last-reviewed date checked before sign-off:

• Drafting — a subject-matter expert writes the article using only primary and peer-reviewed sources.
• Internal review — a second reviewer cross-checks every numerical claim against the cited document.
• Editorial sign-off — the editorial team verifies scientific accuracy, regulatory-status accuracy, compliance wording, and consistency with the rest of the library.
• Post-publication monitoring — articles are re-reviewed when new clinical data, regulatory decisions, broken citations, or reader reports trigger an update.

For source hierarchy and what we will not cite, see research standards. Approval trackers and regulatory-status pages are prioritized for refresh immediately after a primary-source event; evergreen explainers, dosage guides, and comparison pages are re-reviewed on a rolling quarterly cadence or sooner when material new data appears.

The team holds backgrounds in pharmaceutical sciences, biochemistry and HPLC analytical chemistry, and clinical research methodology (Phase 2/3 trial design, biostatistics, regulatory filings). English long-form pages may credit Dr. Nadia Haroun, PharmD or the Remy Peptides Research Team; Portuguese pages are adapted from the English source set and re-checked before publication.

• Minor (typos, broken links): fixed on discovery.
• Factual (data, regulatory status, attribution): corrected within 48 hours and logged in the article’s Update History or change note.
• Significant revisions (new data that changes conclusions): full editorial re-review with documented Update History and refreshed citations.

We do not silently alter published claims. Report errors via WhatsApp or the contact page; we review correction requests within 48 hours and preserve material claim changes in public page history.

Remy Peptides sells retatrutide. The library also covers compounds we do not sell (tirzepatide, semaglutide, liraglutide, CagriSema, survodutide, orforglipron, petrelintide, zenagamtide, mazdutide, VK2735). Identical sourcing and verification standards apply regardless of commercial interest. No pharmaceutical company or advertiser has editorial influence, and commercial CTAs are kept outside the core evidence blocks.

All content is written under a For Research Use Only standard. We do not publish treatment claims, diagnostic claims, dosing instructions for human use, or efficacy promises. Regulatory language is framed as status, evidence, observed outcomes, tolerability, and protocol context. UAE MoHAP Circular 17/2022 is the baseline reference for compliance wording across core commercial and trust pages.

We refresh a page when a primary trial readout posts, a regulator changes status, a citation breaks, a product specification changes, or a reader flags a factual issue. Each refresh checks the title, meta description, structured data, visible citations, and internal links so the page copy and metadata stay aligned.